DGX

$250.810.40%-1.01

Quest Diagnostics Inc (DGX)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$251.82

Aprire:

$251.60

Volume 24 ore:

996,956

Volume relativo:

0.94

Capitalizzazione di mercato:

$27.68B

Reddito:

$11.28B

Utile/perdita netta:

$1.07B

Rapporto P/E:

27.67

EPS:

$9.07

Flusso di cassa netto:

$1.33B

1W Prestazione:

+3.40%

1M Prestazione:

+7.49%

6M Prestazione:

+30.18%

1Y Prestazione:

+40.24%

Intervallo 1D:

$0.00$0.00

Intervallo di 1 settimana:

$242.34$256.99

Portata 52W:

$171.18$256.99

Profilo aziendale di Quest Diagnostics Inc (DGX)

Nome

Quest Diagnostics Inc

Settore

Healthcare

Industria

Diagnostics & Research

Telefono

(973) 520-2700

Indirizzo

500 PLAZA DRIVE, SECAUCUS, USA

Dipendente

57,000

@QuestDX

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di DGX su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Quest Diagnostics Inc Azioni (DGX) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-01-30	Aggiornamento	Barclays	Equal Weight → Overweight
2025-08-25	Downgrade	Robert W. Baird	Outperform → Neutral
2025-04-02	Iniziato	Redburn Atlantic	Buy
2025-03-04	Downgrade	Citigroup	Buy → Neutral
2025-01-06	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-12-17	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Resumed	Jefferies	Buy
2024-10-23	Aggiornamento	Robert W. Baird	Neutral → Outperform
2024-08-28	Resumed	Evercore ISI	In-line
2024-07-10	Aggiornamento	Citigroup	Neutral → Buy
2024-02-26	Iniziato	Leerink Partners	Market Perform
2024-02-07	Aggiornamento	Jefferies	Hold → Buy
2024-01-03	Iniziato	Barclays	Equal Weight
2023-12-12	Aggiornamento	BofA Securities	Neutral → Buy
2023-06-29	Iniziato	Piper Sandler	Neutral
2023-05-02	Downgrade	BofA Securities	Buy → Neutral
2023-04-03	Aggiornamento	Citigroup	Sell → Neutral
2023-01-23	Iniziato	Evercore ISI	In-line
2022-11-17	Downgrade	Citigroup	Neutral → Sell
2022-08-22	Resumed	Morgan Stanley	Equal-Weight
2022-04-04	Downgrade	Citigroup	Buy → Neutral
2022-02-23	Downgrade	UBS	Buy → Neutral
2022-02-02	Downgrade	Jefferies	Buy → Hold
2022-01-28	Downgrade	Deutsche Bank	Buy → Hold
2021-05-04	Aggiornamento	UBS	Neutral → Buy
2021-03-12	Downgrade	Robert W. Baird	Outperform → Neutral
2020-10-21	Aggiornamento	Argus	Hold → Buy
2020-07-29	Aggiornamento	KeyBanc Capital Markets	Sector Weight → Overweight
2020-07-14	Aggiornamento	BofA Securities	Neutral → Buy
2020-06-09	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2020-06-02	Aggiornamento	Deutsche Bank	Hold → Buy
2020-04-28	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-04-27	Aggiornamento	Citigroup	Neutral → Buy
2020-04-27	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2020-03-27	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-01-08	Iniziato	Wells Fargo	Underweight
2020-01-07	Downgrade	Barclays	Overweight → Equal Weight
2019-12-19	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-07-15	Downgrade	Goldman	Neutral → Sell
2019-04-02	Aggiornamento	Jefferies	Hold → Buy
2019-03-18	Resumed	Credit Suisse	Neutral
2019-01-31	Downgrade	Argus	Buy → Hold
2019-01-17	Iniziato	UBS	Neutral
2019-01-03	Downgrade	BofA/Merrill	Neutral → Underperform
2018-12-03	Downgrade	BofA/Merrill	Buy → Neutral
2018-11-30	Downgrade	Goldman	Buy → Neutral

Quest Diagnostics Inc Azioni (DGX) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	11,035.00	9,872.00	9,252.00	9,883.00	10,788.00
Cost of revenue USD (M)	7,370.00	6,628.00	6,199.00	6,450.00	6,579.00
Gross profit USD (M)	-	-	3,053.00	3,433.00	4,209.00
Operating expenses USD (M)	9,479.00	8,526.00	1,791.00	2,005.00	1,828.00
Operating income USD (M)	1,556.00	1,346.00	1,262.00	1,428.00	2,381.00
Income before tax USD (M)	1,318.00	1,175.00	1,130.00	1,235.00	2,599.00
Income tax expense USD (M)	314.00	273.00	248.00	264.00	597.00
Net income USD (M)	1,046.00	921.00	908.00	1,015.00	2,080.00
Basic EPS USD/shares	8.87	7.78	7.59	8.10	15.85
Diluted EPS USD/shares	8.75	7.69	7.49	7.97	15.55
Basic weighted shares shares (M)	111.00	111.00	112.00	116.00	125.00
Diluted weighted shares shares (M)	113.00	113.00	113.00	118.00	128.00
Selling, general and administrative USD (M)	1,967.00	1,770.00	1,642.00	1,874.00	1,727.00

Quest Diagnostics Inc Azioni (DGX) insider trading

PFEIFFER GARY MOct 26 '26
Director
Transazione
Sale
Costo
$243.00
#Azioni
1,203
Valore ($)
292,329
#Azioni Totale
29,802
PFEIFFER GARY MOct 26 '26
Director
Transazione
Proposed Sale
Costo
$243.00
#Azioni
1,203
Valore ($)
292,329
#Azioni Totale
0
Davis J. E.Sep 01 '26
Officer
Transazione
Proposed Sale
Costo
$242.72
#Azioni
10,000
Valore ($)
2,427,200
#Azioni Totale
0
Davis J. E.Sep 01 '26
CEO and President
Transazione
Sale
Costo
$242.72
#Azioni
10,000
Valore ($)
2,427,200
#Azioni Totale
122,423
PREVOZNIK MICHAEL EAug 28 '26
SVP & General Counsel
Transazione
Sale
Costo
$243.11
#Azioni
22,677
Valore ($)
5,513,083
#Azioni Totale
37,557
PREVOZNIK MICHAEL EAug 28 '26
Officer
Transazione
Proposed Sale
Costo
$243.11
#Azioni
22,677
Valore ($)
5,513,082
#Azioni Totale
0
PREVOZNIK MICHAEL EAug 28 '26
SVP & General Counsel
Transazione
Option Exercise
Costo
$112.17
#Azioni
22,677
Valore ($)
2,543,679
#Azioni Totale
60,234
DELANEY MARK EJul 28 '26
SVP & Chief Commercial Officer
Transazione
Sale
Costo
$235.18
#Azioni
1,600
Valore ($)
376,288
#Azioni Totale
10,335
DELANEY MARK EJul 28 '26
Officer
Transazione
Proposed Sale
Costo
$235.18
#Azioni
1,600
Valore ($)
376,288
#Azioni Totale
0
KUPPUSAMY KARTHIKJun 04 '26
SVP, Clinical Solutions
Transazione
Sale
Costo
$200.00
#Azioni
8,147
Valore ($)
1,629,400
#Azioni Totale
13,510

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
PFEIFFER GARY M	Director	Oct 26 '26	Sale	$243.00	1,203	292,329	29,802
PFEIFFER GARY M	Director	Oct 26 '26	Proposed Sale	$243.00	1,203	292,329	0
Davis J. E.	Officer	Sep 01 '26	Proposed Sale	$242.72	10,000	2,427,200	0
Davis J. E.	CEO and President	Sep 01 '26	Sale	$242.72	10,000	2,427,200	122,423
PREVOZNIK MICHAEL E	SVP & General Counsel	Aug 28 '26	Sale	$243.11	22,677	5,513,083	37,557
PREVOZNIK MICHAEL E	Officer	Aug 28 '26	Proposed Sale	$243.11	22,677	5,513,082	0
PREVOZNIK MICHAEL E	SVP & General Counsel	Aug 28 '26	Option Exercise	$112.17	22,677	2,543,679	60,234
DELANEY MARK E	SVP & Chief Commercial Officer	Jul 28 '26	Sale	$235.18	1,600	376,288	10,335
DELANEY MARK E	Officer	Jul 28 '26	Proposed Sale	$235.18	1,600	376,288	0
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Jun 04 '26	Sale	$200.00	8,147	1,629,400	13,510

Quest Diagnostics Inc Borsa (DGX) Ultime notizie

Oct 29, 2026

Quest Diagnostics class action alleges data breach exposed patient medical records - Claim Depot

Oct 29, 2026

Oct 28, 2026

Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 28, 2026

Quest Diagnostics faces multiple class action lawsuits over lab data breach - Top Class Actions

Oct 28, 2026

Evercore ISI Adjusts Price Target on Quest Diagnostics to $240 From $235 - marketscreener.com

Oct 28, 2026

Oct 27, 2026

Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends? - Zacks Investment Research

Oct 27, 2026

Quest Diagnostics data breach hits patient records in lab system - Top Class Actions

Oct 27, 2026

Oct 26, 2026

Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's - Seeking Alpha

Oct 26, 2026

Form 144 QUEST DIAGNOSTICS INC For: 26 October By Investing.com - Investing.com India

Oct 26, 2026

Form 144 QUEST DIAGNOSTICS INC For: 26 October By Investing.com - Investing.com Canada

Oct 26, 2026

Form 144 QUEST DIAGNOSTICS INC For: 26 October By Investing.com - Investing.com UK

Oct 26, 2026

A director proposes selling 1,203 shares of Quest Diagnostics (NYSE: DGX). - Stock Titan

Oct 26, 2026

Oct 23, 2026

Quest Diagnostics Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Unauthorized Access to Patient Records - Morningstar

Oct 23, 2026

Quest Diagnostics 3Q 2026: Revenue $3.1B, Net income $312M, EPS $2.78— 10-Q Summary - TradingView

Oct 23, 2026

Quest Diagnostics investigating data breach involving patient records - Tri-State Alert

Oct 23, 2026

Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach - TechCrunch

Oct 23, 2026

Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term - Zacks Investment Research

Oct 23, 2026

Quest Diagnostics reports unauthorized access to lab system, says patient information may have been compromised - WRNJ Radio

Oct 23, 2026

Quest Diagnostics Data Breach Exposed ‘Certain Patient Records’ - SecurityWeek

Oct 23, 2026

Oct 22, 2026

Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $254.5, Implies 7% Upside - TradingView

Oct 22, 2026

Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance

Oct 22, 2026

Quest Diagnostics confirms patient information accessed in cyberattack, systems temporarily shut down - Fox Business

Oct 22, 2026

Quest Diagnostics’ test results system breached in yet another medtech cyberattack - RamaOnHealthcare

Oct 22, 2026